Please assess the completion status of the following clinical trial:

Trial Title: Eribulin in HER2 Negative Metastatic BrCa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven invasive breast cancer, locally recurrent or metastatic, with at least one measureable lesion according to RECIST v1.1~* Hormone receptor positive or hormone receptor negative HER2-negative disease~* Up to one prior line of chemotherapy for advanced disease is allowed (discontinued at least 14 days prior to initiation of protocol therapy)~* Prior bevacizumab in the neo/adjuvant or metastatic setting is acceptable~* No limit on prior lines of endocrine therapy, but must be discontinued at least 7 days prior to initiation of protocol therapy~* Must have completed any prior radiotherapy at least 2 weeks prior to initiation of protocol therapy~* Must have recovered from reversible effects of prior therapies to no more than grade 1 toxicity, with the exception of alopecia~* Agree to use adequate contraception for the duration of study participation~Exclusion Criteria:~* Pregnant or breastfeeding~* Prior treatment with eribulin~* Prior malignancy other than carcinoma in situ of the cervix or nonmelanoma skin cancer unless diagnosed and definitively treated at least 3 years before enrollment in this study~* Clinically significant cardiovascular impairment~* Active brain metastases or unevaluated neurologic symptoms suggestive of brain metastases~* Pulmonary dysfunction requiring the use of oxygen~* Prior organ allograft requiring immunosuppression~* HIV positive on combination antiretroviral therapy~* Pre-existing grade 3 or 4 neuropathy~* Hypersensitivity to halichondrin B or halichondrin B chemical derivative~* Uncontrolled intercurrent illness~* Inability to read in English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: HR+/HER2- (Type: EXPERIMENTAL): Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle~Participants remained on single agent eribulin until disease progression or withdrawal for other reasons.
- Cohort 2: TNBC (Type: EXPERIMENTAL): Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle~Participants remained on single agent eribulin until disease progression or withdrawal for other reasons.

Based on this trial design, predict the completion outcome and termination type (if applicable).